Augmedix Stock – A Remote Clinical Documentation IPO

We don’t usually do this sort of stuff, but we’d like to start this article off letting everyone know about an exciting SPAC opportunity. John from Cameroon – a region in the great country of Africa – emailed us about a pre-revenue cosmetics/wood timber/software development outsourcing company that’s looking for a SPAC to have an IPO with. They’re dabbling in a bit of everything, so we’re not sure how to do the comparables slide which benchmarks their lofty 2024-2025 revenue estimates against someone else’s lofty 2024-2025 revenue estimates, but if you’re interested, give us a shout.

Moving on, today we’re going to talk about a SPAC-like merger for a company that’s a bit more focused. Augmedix is a startup we came across a while back that was developing a service offering which lets doctors use Google Glass during facetime with patients to reduce the need to take notes during consultations. Now, they’ve decided to go public using a shell company called Malo Holdings Corporation. Unlike most SPACs, Augmedix actually provided loads of information in their SEC filing for our hungry MBAs to digest.

About Augmedix Stock

Click for company website

Founded in 2013, San Francisco startup Augmedix has taken in $82 million in disclosed funding so far to create a remote medical documentation offering. Simply put, they use hardware like Google Glass, or an app on the doctor’s smartphone, to capture audio and/or video during patient consultations, and then use the output to populate

You’ve used your quota of premium articles. To continue reading, please sign up to one of our premium plans.
Or create a free account to unlock just this article

Unlock 2 extra premium articles each month for free.

Sign up for our free weekly newsletter and unlock 2 extra premium articles every month. Plus, each week, we’ll send you insights from our team of underpaid MBAs, coverage of disruptive tech stocks flying under the radar, and summaries of our newest reports. Always free. No spam. No hype.